1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Petit, M.C. Benkirane, N. Guichard, G. Phan Chan Du, A. Cung, M.T. Briand, J.P. Muller, S. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 1 90.00 90.00 90.00 1.000 1.000 1.000 C2 H4 O 44.053 ACETYL GROUP non-polymer C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking US J.Biol.Chem. JBCHA3 0071 0021-9258 274 3686 3692 10.1074/jbc.274.6.3686 9920919 Solution structure of a retro-inverso peptide analogue mimicking the foot-and-mouth disease virus major antigenic site. Structural basis for its antigenic cross-reactivity with the parent peptide. 1999 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 1972.235 PEPTIDE CORRESPONDING TO THE MAJOR IMMUNOGEN SITE OF FMD VIRUS 1 man polymer no yes (ACE)GSGVRGDFGSLAPRVARQL XGSGVRGDFGSLAPRVARQL A polypeptide(L) n n n n n n n n n n n n n n n n n n n n pdbx_database_status pdbx_struct_assembly pdbx_struct_oper_list struct_conf repository Initial release Version format compliance Version format compliance Derived calculations Other 1 0 1998-11-25 1 1 2008-03-24 1 2 2011-07-13 1 3 2017-11-29 _pdbx_database_status.process_site Y BNL 1998-05-03 REL G-H LOOP OF THE PROTEIN VP1 sample target function 50 10 COSY TOCSY ROESY NOESY 0.1M PHOSPHATE 5.7 1 atm 285 K RESTRAINED ENERGY REFINEMENT. torsion angle dynamics H2O GUNTERT,WUTHRICH refinement DYANA 1.4 structure solution DYANA-1.4 400 Bruker DRX400 ACE 140 n 1 ACE 140 A GLY 141 n 2 GLY 141 A SER 142 n 3 SER 142 A GLY 143 n 4 GLY 143 A VAL 144 n 5 VAL 144 A ARG 145 n 6 ARG 145 A GLY 146 n 7 GLY 146 A ASP 147 n 8 ASP 147 A PHE 148 n 9 PHE 148 A GLY 149 n 10 GLY 149 A SER 150 n 11 SER 150 A LEU 151 n 12 LEU 151 A ALA 152 n 13 ALA 152 A PRO 153 n 14 PRO 153 A ARG 154 n 15 ARG 154 A VAL 155 n 16 VAL 155 A ALA 156 n 17 ALA 156 A ARG 157 n 18 ARG 157 A GLN 158 n 19 GLN 158 A LEU 159 n 20 LEU 159 A author_defined_assembly 1 monomeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 identity operation 0.0000000000 0.0000000000 0.0000000000 1 A SER 142 -99.15 59.47 1 A VAL 144 175.11 116.49 1 A ALA 156 -139.59 -46.25 2 A SER 142 -51.61 173.49 2 A VAL 144 175.10 116.47 2 A ALA 156 -139.55 -46.25 3 A VAL 144 175.03 116.43 3 A ASP 147 -47.36 159.86 3 A ARG 154 -111.01 71.12 3 A ALA 156 -139.58 -46.25 4 A VAL 144 175.07 116.49 4 A ARG 145 -39.81 112.61 4 A ALA 156 -139.62 -46.17 5 A VAL 144 175.09 116.46 5 A ARG 145 -166.49 107.71 5 A ALA 156 -139.68 -46.23 6 A SER 142 -113.16 59.64 6 A VAL 144 175.10 116.47 6 A PHE 148 -46.61 172.44 6 A ALA 156 -139.61 -46.21 7 A VAL 144 175.07 116.49 7 A PHE 148 -41.69 158.69 7 A LEU 151 -45.06 165.08 7 A ALA 156 -139.60 -46.20 8 A VAL 144 175.07 116.46 8 A ARG 154 -151.83 88.96 8 A ALA 156 -139.81 -46.26 9 A SER 142 -151.85 55.22 9 A VAL 144 175.07 116.46 9 A ARG 145 -167.82 96.95 9 A ALA 156 -140.47 -45.90 10 A SER 142 -167.47 58.93 10 A VAL 144 175.06 116.48 10 A ARG 145 -56.49 106.06 10 A ALA 156 -140.48 -45.86 model building DYANA refinement DYANA PEPTIDE CORRESPONDING TO THE MAJOR IMMUNOGEN SITE OF FMD VIRUS SYNTHETIC PEPTIDE CORRESPONDING TO THE MAJOR IMMUNOGEN SITE OF FMD VIRUS, NMR, 10 STRUCTURES 1 Y N covale 1.325 A ACE 140 A C ACE 1 1_555 A GLY 141 A N GLY 2 1_555 SYNTHETIC PEPTIDE SYNTHETIC PEPTIDE, ANTIGENE POLG_FMDVA UNP 1 1 P03308 MNTTNCFIALVHAIREIRAFFLSRATGKMEFTLYNGERKTFYSRPNNHDNCWLNTILQLFRYVDEPFFDWVYNSPENLTL AAIKQLEELTGLELHEGGPPALVIWNIKHLLQTGIGTASRPARCMVDGTNMCLADFHAGIFLKEQEHAVFACVTSNGWYA IDDEDFYPWTPDPSDVLVFVPYDQEPLNGGWKANVQRKLKGAGQSSPATGSQNQSGNTGSIINNYYMQQYQNSMDTQLGD NAISGGSNEGSTDTTSTHTTNTQNNDWFSKLASSAFTGLFGALLADKKTEETTLLEDRILTTRNGHTTSTTQSSVGVTYG YSTEEDHVAGPNTSGLETRVVQAERFFKKFLFDWTPDKPFGHRTKLELPTDHHGVFGHLVDSYAYMRNGWDVEVSAVGNQ FNGGCLLVAMVPEWKTFDTREEYQLTLFPHQFISPRTNMTAHITVPYLGVNRYDQYKKHKPWTLVIMVLSPLTVSNTAAT QIKVYANIAPTYVHVAGELPSKVGIFPVACSDGYGGLVTTDPKTADPVYGKEYNPPKTNYPRRFTNLLDVAEACPTFLCF DDGKPYVVTRTDDTRLLAKFDVSLAAKHMSNTYLSGIAQYYTQYSGTINLHFMFTGSTDSKARYMVAYIPPGVETPPETP EGAAHCIHAEWDTGLNSKFTFSIPYVSAADYAYTASDTAETTNVQGWVCIYQITHGKAEDDTLVVSASAGKDFELRLPID PRSQTTATGESADPVTTTVENYGGETQVQRRHHTDVSFIMDRFVKIKSLNPTHVIDLMQTHQHGLVGALLRAATYYFSDL EIVVRHDGNLTWVPNGAPEAALSNTGNPTAYNKAPFTRLALPYTAPHRVLATVYNGTNKYSASGSGVRGDFGSLAPRVAR QLPASFNYGAIKAETIHELLVRMKRAELYCPRPLLAIEVSSQDRHKQKIIAPGKQLLNFDLLKLAGDVESNPRPFFFADV RSNFSKLVDTINQMQEDMSTKHGPDFNRLVSAFEELATGVKAIRTGLDEAKPWYKLIKLLSRLSCMAAVAARTKDPVLVA IMLADTGLEILDSTFVVKKISDSLSSLFHVPAPVFSFGAPVLLAGLVKVASSFLRSTPEDLERAEKQLKARDINDIFAIL KNGEWLVKLILAIRDWIKAWIASEEKFVTMTDLVLGILEKQRDLNDPSKYKEAKEWLDNARQACLKSGNVHIANLCKVVA PAPSKSRPEPVVVCLRGKSGQGKSFLANVLAQAISTHFTGRTDSVWYCPPDPDHFDGYNQQTVVVMDDLGQNPDGKDFKY FAQMVSTTGFIPPMASLEDKGKPFNSKVIIATTNLYSGFTPRTMVCPDALNRRFHFDIDVSAKDGYKINNKLDIVKALED THTNPVAMFQYDCALLNGMAVEMKRMQQDMFKPQPPLQNVYQLVQEVIERVELHEKVSSHPIFKQISIPSQKSVLYFLIE KGQHEAAIEFFEGMVHDSIKEELRPLIQQTSFVKRAFKRLKENFEIVALCLTLLANIVIMIRETRKRQKMVDDAVNEYIE KANITTDDTTLDEAEKNPLETSGASTVGFRERTLTGQRACNDVNSEPARPAEEQPQAEGPYTGPLERQRPLKVRAKLPQQ EGPYAGPLERQKPLKVKAKAPVVKEGPYEGPVKKPVALKVKAKNLIVTESGAPPTDLQKMVMGNTKPVELILDGKTVAIC CATGVFGTAYLVPRHLFAEKYDKIMLDGRAMTDSDYRVFEFEIKVKGQDMLSDAALMVLHRGNRVRDITKHFRDTARMKK GTPVVGVVNNADVGRLIFSGEALTYKDIVVCMDGDTMPSLFAYKAATKAGYCGGAVLAKDGADTFIVGTHSAGGNGVGYC SCVSKSMLLRMKAHVDPEPQHEGLIVDTRDVEERVHVMRKTKLAPTVAHGVFNPEFGPAALSNKDPRLNEGVVLDEVIFS KHKGDTKMSAEDKALFRACAADYASRLHSVLGTANAPLSIYEAIKGVDGLDAMESDTAPGLPWAFQGKRRGALIDFENGT VGPEVEAALKLMEKREYKFVCQTFLKDEIRPMEKVRAGKTRIVDVLPVEHILYTRMMIGRFCAQMHSNNGPQIGSAVGCN PDVDWQRFGTHFAQYRNVWDVDYSAFDTNHCSDAMNIMFEEVFRTDFGFHPNAEWILKTLVNTEHAYENKRITVEGGMPS DCSATGIINTILNNIYVLYALRRHYEGVELDTYTMISYGDDIVVASDYDLDFEALKPHFKSLGQTITPADKSDKGFVLGH SITDVTFLKRHFHIDYGTGFYKPVMASKTLEAILSFARRGTIQEKLTSVAGLAVHSGPDEYRRLFEPFQGLFEIPSYRSL YLRWVNAVCGDA 864 882 1BCV 141 159 P03308 A 1 2 20 1 P 1